RayzeBio, Inc. Common Stock (RYZB)
RayzeBio, Inc. Common Stock operates in the Biotechnology industry of the Healthcare sector, headquartered in DE, US. The stock last traded at $62.49, up 0.02% on the session, giving a market capitalisation of $3.75B. On trailing twelve-month figures it carries a trailing P/E of -35.71, a net margin of 0.0%. Its beta of 3.79 implies it has historically moved more than the broad market.
RayzeBio, Inc. is dedicated to creating radiopharmaceutical therapies (RPTs) for oncology applications. Its primary therapeutic candidate, RYZ101, is currently advancing through Phase 3 clinical trials for the management of gastroenteropancreatic neuroendocrine tumors (GEP-NETs). The company's innovative pipeline also features RYZ801, a distinct peptide engineered to deliver Actinium-225 (Ac225) by targeting GPC3, intended for treating hepatocellular carcinoma (HCC). Additionally, RayzeBio is developing RYZ811, a companion diagnostic imaging agent comprising a peptide binder, a chelator, and Gallium-68 (Ga68). Another active development program involves a novel proprietary small molecule designed to target CA9, delivering Ac225 for potential use against clear cell renal cell carcinoma (ccRCC). The firm was established in 2020 and is headquartered in San Diego, California.
RayzeBio, Inc. Common Stock is most often compared with the following Healthcare names: